GRG Health captured real-world insights from 75 oncologists across the U.S., Germany, and France in just 10 days. The study revealed strong support for gene therapies and critical gaps in BCG-unresponsive treatment options. These insights powered smarter portfolio decisions and accelerated go-to-market strategies in HR-NMIBC.
Summary
Discover how GRG Health captured oncologist insights across 3 markets to shape the future of HR-NMIBC treatment.
A leading market research initiative set out to understand the evolving treatment landscape of high-risk non-muscle invasive bladder cancer (HR-NMIBC) across the U.S., Germany, and France.
The challenge? Limited access to specialized oncologists, inconsistent data, and cross-cultural complexity.
Using a rigorous, localized, AI-supported approach, the study delivered:
✅ Insights from 75 bladder cancer specialists in 10 business days
✅ 100% use BCG as first-line; 70% dissatisfied with BCG-unresponsive options
✅ 85% support gene therapies; 65% cautious on checkpoint inhibitors
✅ 90% value guideline inclusion; 95% rely on clinical trial data
✅ U.S. oncologists are nearly 2x more likely to trial investigational therapies
The study enabled smarter portfolio decisions and supported go-to-market strategies for a fast-evolving therapy area.
Interested in knowing more? Fill out the form to download the case study and see how GRG Health helps life sciences stay ahead of the curve.
Meet the Author
